home / stock / annx / annx news

ANNX News and Press, Annexon Inc. From 08/11/25

Stock Information
Company Name: Annexon Inc.
Stock Symbol: ANNX
Market: NASDAQ
Website: annexonbio.com
Menu
ANNX ANNX Quote ANNX Short ANNX News ANNX Articles ANNX Message Board
Get ANNX Alerts

News, Short Squeeze, Breakout and More Instantly...
ANNX - Expected earnings - Annexon Inc.

Annexon Inc. (ANNX) is expected to report $-0.36 for Q2 2025
ANNX - Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument Has the Potential to Be the Fir...

ANNX - Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation Topline Pivotal Phase 3 ...

ANNX - Annexon Inc. (NASDAQ: ANNX) Sees Notable Increase in Wednesday Morning Market Activity

2025-07-02 11:09:31 ET Annexon, Inc. (NASDAQ: ANNX) is one of today’s top gainers. The company’s shares have moved 18.83% on the day to $2.94. Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerati...
ANNX - Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and C...

ANNX - Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today a...

ANNX - Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses...
ANNX - Neutral Recommendation Issued On ANNX By Piper Sandler

2025-05-13 11:15:03 ET Piper Sandler analyst issues NEUTRAL recommendation for ANNX on May 13, 2025 11:53AM ET. The previous analyst recommendation was Neutral. ANNX was trading at $1.74 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

ANNX - Buy Recommendation Issued On ANNX By Canaccord Genuity

2025-05-13 11:15:03 ET Canaccord Genuity analyst issues BUY recommendation for ANNX on May 13, 2025 11:53AM ET. The previous analyst recommendation was Buy. ANNX was trading at $1.74 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

ANNX - Buy Recommendation Issued On ANNX By Benchmark

2025-05-13 10:15:03 ET Benchmark analyst issues BUY recommendation for ANNX on May 13, 2025 11:53AM ET. The previous analyst recommendation was Buy. ANNX was trading at $1.74 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...
Previous 10 Next 10